# L40.0 (PSORIASIS VULGARIS)
<b style="font-size:30px"><u>Plague Psoriasis</u></b>

## <b  style="color:red">Topical Treatments</b>

### <u  style="color:teal">Corticosteroids</u>
- Hydrocortisone (e.g., over-the-counter mild formulations)
- Triamcinolone (e.g., Trianex)
- Clobetasol (e.g., Cormax, Temovate)
- Betamethasone (e.g., Diprolene)
- Fluocinonide (e.g., Lidex)
- Desoximetasone (e.g., Topicort)

### <u  style="color:teal">Vitamin D Analogues</u>
- Calcipotriene (e.g., Dovonex, Sorilux)

### <u  style="color:teal">Retinoids</u>
- Tazarotene (e.g., Tazorac, Avage)

### <u  style="color:teal">Calcineurin Inhibitors</u>
- Tacrolimus (e.g., Protopic) – FDA-approved for atopic dermatitis but used off-label for psoriasis.
- Pimecrolimus (e.g., Elidel) – Similarly approved for atopic dermatitis, used off-label.

### <u  style="color:teal">Aryl Hydrocarbon Receptor (AhR) Agonists</u>
- VTAMA – Approved in 2022 for mild, moderate, and severe plaque psoriasis.

### <u  style="color:teal">Phosphodiesterase-4 (PDE4) Inhibitors</u>
- ZORYVE 0.3% – Approved in 2022 for plaque psoriasis, including intertriginous areas, in adults and adolescents 12+.

### <u  style="color:teal">Combination Therapies</u>
- Calcipotriene + Betamethasone (e.g., Enstilar, Taclonex)

## <b  style="color:red">Systemic Treatments (Oral/Non-Biologic)</b>

### <u  style="color:teal">Retinoids</u>
- Acitretin (e.g., Soriatane)

### <u  style="color:teal">Immunosuppressants</u>
- Methotrexate – Weekly oral dosing.
- Cyclosporine (e.g., Neoral) – For severe cases, short-term use recommended.

### <u  style="color:teal">Phosphodiesterase-4 (PDE4) Inhibitors</u>
- OTEZLA 30MG – Approved for mild-to-severe psoriasis.

### <u  style="color:teal">Tyrosine Kinase 2 (TYK2) Inhibitors</u>
- SOTYKTU 6MG – Approved in 2022 for moderate-to-severe plaque psoriasis.

## <b  style="color:red">Biologics (Injectable)</b>
!!! tip "Important"
    With biologics, it is <u>necessary</u> to invlude thoose lines (even if some portions was answered during Q&A)

    ```
    Patient will continue using topical emollients in problem areas. 
    Patient will not be on any biologics, jak inhibiters, or immunossupressants. 
    Patient is not immunocompromised.
    ```

### <u  style="color:teal">Tumor Necrosis Factor-alpha (TNF-alpha) Inhibitors</u>
- ENBREL
- HUMIRA
- HADLIMA
- CIMZIA

### <u  style="color:teal">Interleukin-12/23 Inhibitors</u>
- STELARA 45MG/90MG – Approved for adults and children 6+.

### <u  style="color:teal">Interleukin-17 (IL-17) Inhibitors</u>
- COSENTYX – Approved for adults and children 6+.
- TALTZ – Approved for adults and children 6+.
- SILIQ – For moderate-to-severe psoriasis, with a boxed warning for suicidal ideation.
- BIMZELX – Approved in 2023, targets IL-17A and IL-17F.

### <u  style="color:teal">Interleukin-23 (IL-23) Inhibitors</u>
- TREMFYA
- ILUMYA
- SKYRIZI

!!! note 
    1. Biosimilars: Several TNF-alpha inhibitors (e.g., adalimumab, infliximab, etanercept) have FDA-approved biosimilars (e.g., Amjevita for Humira). These are "highly similar" alternatives and may be used interchangeably depending on availability and insurance.
    2. Pending Approvals: As of March 5, 2025, roflumilast foam (Zoryve foam 0.3%) is under FDA review for scalp and body psoriasis with a PDUFA date of May 22, 2025.
    3. Off-Label Use: Some medications (e.g., tacrolimus, hydroxyurea) are not FDA-approved specifically for psoriasis but are used off-label in certain cases.
    4. Children: Specific approvals for pediatric use are noted where applicable (e.g., etanercept, ustekinumab, secukinumab, ixekizumab).
